Granules Pharmaceuticals 获得了 FDA 的仿制药 ADHD 治疗批准，增加了 68 项批准。 Granules Pharmaceuticals receives FDA approval for a generic ADHD treatment, adding to their 68 approvals.

Granules India Limited的子公司,即Granules India Limited公司下属的Granules制药公司,已获得林业发展局批准其通用版的用于治疗ADHD的Lisdexamfetamine Dimesylate Chewable平板药。 Granules Pharmaceuticals, Inc., a subsidiary of Granules India Limited, has received FDA approval for its generic version of Lisdexamfetamine Dimesylate Chewable Tablets, used to treat ADHD. 该药物被认为等同于Takeda的Vyvanse,具有多种长处。 The drug is considered equivalent to Takeda's Vyvanse and is available in multiple strengths. 这项批准是Granules帮助缓解药物短缺努力的一部分,现在使林业发展局的批准总数达到68项。 This approval is part of Granules' effort to help alleviate drug shortages and now brings their total FDA approvals to 68.